BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.60 Consensus Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $15.60.

BCRX has been the subject of several recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. JMP Securities increased their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 6th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. Series C raised its position in shares of BioCryst Pharmaceuticals by 62.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock worth $50,279,000 after acquiring an additional 3,140,804 shares in the last quarter. Geode Capital Management LLC raised its position in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after acquiring an additional 127,708 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock worth $16,576,000 after acquiring an additional 261,500 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its position in shares of BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after acquiring an additional 84,102 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded up $0.19 during trading on Wednesday, hitting $7.38. The company had a trading volume of 1,032,366 shares, compared to its average volume of 2,884,173. The firm has a market capitalization of $1.53 billion, a P/E ratio of -11.79 and a beta of 1.79. The stock's 50-day moving average price is $7.58 and its 200 day moving average price is $7.32. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same quarter last year, the firm posted ($0.19) earnings per share. The company's quarterly revenue was up 35.1% on a year-over-year basis. On average, research analysts anticipate that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.